Modern Possibilities of Metabolic Therapy in Improving the Quality of Life in Patients with Postinfarction Cardiosclerosis
American Journal of Internal Medicine
Volume 7, Issue 4, July 2019, Pages: 86-92
Received: Jun. 24, 2019;
Accepted: Jul. 16, 2019;
Published: Jul. 26, 2019
Views 379 Downloads 67
Vasilieva Irina, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
Rezvan Vladimir, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
Dvoretskiy Leonid, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
Follow on us
95 patients with postinfarction cardiosclerosis and angina pectoris II and III functional classes were examined. The study included patients who refused intervention revascularization. The main group included 48 patients who were added taurine (Dibikor 750 mg / day) to enhance the effect of basic therapy, and the comparison group included 47 patients who received standard therapy and placebo. The duration of treatment was 3 months. The study demonstrated positive effects of taurine that was confirmed by significant improvements in the following indicators: subjective status, indicators of the Seattle questionnaire, echocardiographic parameters, cardiac arrhythmias. There was a decrease in the severity of fatigue by 2 times, a decrease in the intensity of complaints of palpitations by 72.3%, a decrease in the severity of dyspnea by 30.0% and a severity of pain in the heart area by 50%. Indicators of most scales of the Seattle questionnaire in patients of the main group at the end of the study significantly exceeded (p <0.05) the corresponding values in patients of the comparison group. In patients whose treatment was used taurine, a significant improvement in inotropic function was noted (the ejection fraction is significantly higher than in the comparison group, respectively 56.0 ± 1.8 and 53.5 ± 1.1%, p <0,05), the bathmotropic and chronotropic myocardial functions improved, which was shown by a 45% decrease in the number of ventricular extrasystoles, a 57% decrease in the frequency of supraventricular heart rhythm disturbances, a decrease in the incidence rate of ST segment depression (in the main group the number of episodes was significantly lower than p <0,05 than in the comparison group). The use of taurine in the complex treatment of patients with exertional angina, after suffering a myocardial infarction, is safe and not accompanied by side effects. Taurine is advisable to include in the complex treatment of patients with exertional angina pectoris, who have had a myocardial infarction in order to improve the myocardial inotropic function, enhance the antiarrhythmic and lipid-lowering effects of the basic therapy. The recommended dose of Taurine is 750 mg per day as a supplement to standard therapy with a duration of therapy of at least 3 months.
Angina, Postinfarction Cardiosclerosis, Taurine, Quality of Life, Exercise Tolerance, Cardiac Arrhythmias
To cite this article
Modern Possibilities of Metabolic Therapy in Improving the Quality of Life in Patients with Postinfarction Cardiosclerosis, American Journal of Internal Medicine.
Vol. 7, No. 4,
2019, pp. 86-92.
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Van de Werf F, Crea F. The year in cardiology 2014: acute coronary syndromes. Eur. Heart J. 2015; 36: 342-6. DOI: 10.1093 / eurheartj / ehu488. Epub 2015 Jan 2.
Nayyar S, Wilson L, Ganesan A, et al. Electrophysiologic features of protected channels in late postinfarction patients with and without spontaneous ventricular tachycardia. J. Interv. Card Electrophysiol. 2017; Dec 13. DOI: 10.1007 / s10840-017-0299-6. [Epub ahead of print].
Cacciapuoti F, Tirelli P. Left ventricular postinfarctionseudoaneurysm: Diagnostic Advantages of Three-Dimensional Echocardiography. J CardiovascEchogr. 2017; 27 (2): 74-6. DOI: 10.4103 / jcecho.jcecho_49_16.
Allo SN, Bagby L, Schaffer SW. Taurine depletion, a novel mechanism for cardioprotection from regional ischemia. Am. J. Physiol. 1997; 273: 1956-61.
Dyakova NA, Puzyreva IN, Ogaj MA, et al. Development of dosage forms with taurine. Bulletin of Voronezh State University. Series: Chemistry. Biology. Pharmacy. 2016; 1: P. 140-6.
Doskina EV. What is taurine and “with what it is eaten”? Questions of dietetics. 2015; 5 (1): 58-61.
Nechaeva GI, Druk IV, Ryapolova EA. Efficacy and tolerability of taurine in patients with type 2 diabetes mellitus and left ventricular diastolic dysfunction. Polyclinic. 2015; 1: 58-62.
Schaffer SW, Shimada-Takaura K, Jong CJ, et al. Impaired energy metabolism of the taurinedeficient heart. Amino Acids. 2016; 48 (2): 549-58. DOI: 10.1007 / s00726-015-2110-2.
Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am CollCardiol. 1995; 25 (2): 333-41.
Stacenko ME, Turkina SV, Shilina NN, Vinnikova AA. Endothelioprotective properties of taurine in patients with chronic heart failure and type 2 diabetes mellitus. Cardiovascular Therapy and Prevention. 2016; 15 (2): 38-44.
Averin E. Use of taurine during rehabilitation after cardiac surgery. Adv. Exp. Med. Biol. 2015; 803: 637-649. DOI: 10.1007 / 978-3-319-15126-7_51.